UNIVERSAL BIOSENSORS INC. - ASX Briefs

*Disclaimer

UNIVERSAL BIOSENSORS INC. (ASX: UBI)

UBI: UBI launches PETRACKR Diabetes product for dogs and cats

UNIVERSAL BIOSENSORS INC.

Universal Biosensors launches PETRACKR blood glucose monitoring product for diabetic dogs and cats globally.
UBI signs three distribution partnerships in the USA and Canada, with first-year sales value expected to exceed $2 million.
PETRACKR aims to provide better performance, accuracy, and pricing in the growing pet diabetes market, estimated to be $270 million p.a.

2023-05-03 08:19:00

UBI: UBI launch sixth new Sentia Test

UNIVERSAL BIOSENSORS INC.

Universal Biosensors has launched its sixth product on the Sentia wine testing platform, Titratable Acidity.
Titratable Acidity is a crucial measurement for wine, affecting taste and stability, and is tested continuously throughout the year.
Sales of Sentia products are growing strongly, with a Q123 vs Q122 increase of 188%, 165 devices in wineries, and over 65,000 strips sold.

2023-04-20 08:12:00

UBI: UBI submits Xprecia Prime 510K Application to FDA

UNIVERSAL BIOSENSORS INC.

Universal Biosensors (UBI) has submitted a 510K application to the FDA for approval of Xprecia Prime.
The application includes a 360 patient study to provide evidence of the platform's performance and safety.
Approval to sell Xprecia Prime in the USA is expected to add significant value to UBI's coagulation business.

2023-03-24 10:45:00

UBI: UBI launch another new Sentia Test

UNIVERSAL BIOSENSORS INC.

Universal Biosensors, Inc. has launched an Acetic Acid biosensor test as the 5th test available on the Sentia wine testing platform.
Acidity in wine is of utmost importance for its quality and taste, and high levels of Acetic acid are considered a fault.
Continuous monitoring of Acetic acid is therefore important for wineries in the northern hemisphere during fermentation and maturation periods.

2023-02-21 08:32:00

UBI: UBI makes first sales of Xprecia Prime in Europe

UNIVERSAL BIOSENSORS INC.

Universal Biosensors, Inc. (ASX:UBI) has delivered the first Xprecia Prime devices to Europe.
John Sharman, CEO of UBI, said that this was a significant achievement for the company and marks the beginning of their new coagulation business.
The sales performance for the coagulation business has been impacted by supply chain issues and the unwinding of the Siemens Healthineers relationship.

2023-02-06 08:58:00

UBI: UBI launches new product - Fructose Test for Sentia

UNIVERSAL BIOSENSORS INC.

Universal Biosensors, Inc. has launched its Fructose biosensor test and relaunched its Glucose test.
The tests are used to measure Total Residual Sugar during winemaking process.
Glucose and Fructose are the main fermentable sugars found in wine.

2023-01-30 08:37:00

UBI: UBI completes Xprecia Prime clinical trial in USA

UNIVERSAL BIOSENSORS INC.

Universal Biosensors, Inc. has completed its 360-patient “Xprecia Prime” PT/INR blood coagulation clinical study in the USA.
The clinical study is being used to provide evidence for UBI’s 510K submission to the FDA, which is expected to be lodged during Q1 2023.
UBI has spent over 10 years developing its Point of Care coagulation platform and the data generated by the clinical study is strong.

2023-01-23 10:21:00